CN1947747A - 由木犀草素和连翘制成的药物组合物及其制备方法和用途 - Google Patents
由木犀草素和连翘制成的药物组合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN1947747A CN1947747A CN 200510104223 CN200510104223A CN1947747A CN 1947747 A CN1947747 A CN 1947747A CN 200510104223 CN200510104223 CN 200510104223 CN 200510104223 A CN200510104223 A CN 200510104223A CN 1947747 A CN1947747 A CN 1947747A
- Authority
- CN
- China
- Prior art keywords
- fructus forsythiae
- luteolin
- injection
- parts
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 title claims abstract description 113
- 235000009498 luteolin Nutrition 0.000 title claims abstract description 110
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 title claims abstract description 106
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 title claims abstract description 106
- 238000000034 method Methods 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims description 48
- 241000555682 Forsythia x intermedia Species 0.000 title abstract 2
- 239000002775 capsule Substances 0.000 title description 14
- 238000010408 sweeping Methods 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 80
- 230000008569 process Effects 0.000 claims abstract description 8
- 239000007924 injection Substances 0.000 claims description 81
- 238000002347 injection Methods 0.000 claims description 81
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- 238000002360 preparation method Methods 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical group C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 claims description 15
- JJVGFDTWFVSBIM-UHFFFAOYSA-N Phillyrin Natural products COc1ccc(cc1OC)C2OCC3C2COC3c4ccc(OC)c(OC5OC(CO)C(O)C(O)C5O)c4 JJVGFDTWFVSBIM-UHFFFAOYSA-N 0.000 claims description 15
- 241000555712 Forsythia Species 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 239000012567 medical material Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 1
- 239000002131 composite material Substances 0.000 abstract description 17
- 206010011224 Cough Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 49
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 239000008215 water for injection Substances 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 15
- 239000008187 granular material Substances 0.000 description 15
- 241000576429 Forsythia suspensa Species 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 229920001214 Polysorbate 60 Polymers 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 10
- 239000008354 sodium chloride injection Substances 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 9
- 238000007689 inspection Methods 0.000 description 9
- 238000012856 packing Methods 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 239000008227 sterile water for injection Substances 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 239000011265 semifinished product Substances 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000000287 crude extract Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000000242 pagocytic effect Effects 0.000 description 5
- -1 phenethyl alcohol glycosides Chemical class 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 201000004595 synovitis Diseases 0.000 description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000007766 cera flava Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000005262 decarbonization Methods 0.000 description 4
- 210000000416 exudates and transudate Anatomy 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000009287 sand filtration Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 239000008347 soybean phospholipid Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 229940013618 stevioside Drugs 0.000 description 4
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 4
- 235000019202 steviosides Nutrition 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 239000013505 freshwater Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000011046 pyrogen test Methods 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-Phenylethanol Natural products OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- SRJCJJKWVSSELL-UHFFFAOYSA-N 2-methylnaphthalen-1-ol Chemical class C1=CC=CC2=C(O)C(C)=CC=C21 SRJCJJKWVSSELL-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000333181 Osmanthus Species 0.000 description 2
- 235000019082 Osmanthus Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- CPJKKWDCUOOTEW-YJPXFSGGSA-N 4-[(3s,3ar,6r,6ar)-6-(3,4-dimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2-methoxyphenol Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O)=CC=3)[C@@H]2CO1 CPJKKWDCUOOTEW-YJPXFSGGSA-N 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 102000009338 Gastric Mucins Human genes 0.000 description 1
- 108010009066 Gastric Mucins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000408529 Libra Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000008503 houttuyninum Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- CPJKKWDCUOOTEW-UHFFFAOYSA-N sylvatesmin Natural products C1=C(OC)C(OC)=CC=C1C1C(COC2C=3C=C(OC)C(O)=CC=3)C2CO1 CPJKKWDCUOOTEW-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 配比 | 给药量(mg/kg) | 肿胀度(mg) | 肿胀抑制率(%) |
对照组木犀草素组连翘组 | --- | -1050 | 2.69±1.252.16±0.35*2.17±0.34* | -19.7019.33 |
木犀草素+连翘 | 20mg+10g20mg+15g20mg+60g20mg+100g50mg+10g50mg+15g50mg+60g50mg+100g100mg+10g100mg+15g100mg+60g100mg+100g | 505050505050505050505050 | 1.98±0.23*1.85±0.21*1.76±0.22*1.65±0.18*1.61±0.14**1.45±0.13**1.43±0.12**1.51±0.15**1.58±0.14**1.56±0.14**1.49±0.11**1.47±0.10** | 26.3931.2234.5738.6640.1546.1046.8443.8741.2642.0144.6145.35 |
菌种 | 组别 | 药品 | 24h生存数 | 24h死亡数 |
金黄色葡萄球菌 | 123456 | 木犀草索注射液连翘注射液木犀草素+连翘(50mg+15g)木犀草素+连翘(50mg+30g)木犀草素+连翘(50mg+60g)氯化钠注射液 | 871010101 | 230009 |
肺炎双球菌 | 123456 | 木犀草素注射液连翘注射液木犀草素+连翘(50mg+15g)木犀草素+连翘(50mg+30g)木犀草素+连翘(50mg+60g)氯化钠注射液 | 88910101 | 221009 |
绿脓杆菌 | 123456 | 木犀草素注射液连翘注射液木犀草素+连翘(50mg+15g)木犀草素+连翘(50mg+30g)木犀草素+连翘(50mg+60g)氯化钠注射液 | 9899100 | 121*1010 |
组别 | 给药量(mg/kg) | 脾脏 | 胸腺 |
空白对照组阳性对照组木犀草素组连翘组木犀草素+连翘(50mg+15g)木犀草素+连翘(50mg+30g)木犀草素+连翘(50mg+60g) | -61050505050 | 2.456±2.5481.686±0.571&5.674±3.511*5.532±3.487**6.012±3.673**6.134±3.681**6.207±3.794** | 2.586±1.0820.423±0.427&3.212±1.435#3.176±1.213#3.686±1.754*3.791±1.811*3.932±1.904* |
组别 | 给药量(mg/kg) | 吞噬率(%) | 吞噬指数 |
空白对照组阳性对照组木犀草素组连翘组木犀草索+连翘(50mg+15g)木犀草素+连翘(50mg+30g)木犀草素+连翘(50mg+60g) | -61050505050 | 68.18±4.5648.13±2.37&78.23±1.45*77.56±1.37*84.23±2.68**86.39±2.97**88.16±2.89** | 1.03±0.160.60±0.13&2.18±0.28#2.16±0.25#2.43±0.31*2.51±0.36*2.58±0.39* |
组别 | 给药量(mg/kg) | 气囊渗出液的OD值 | 气囊渗出液中的白胞数量(108/L) |
生理盐水对照组连翘组木犀草素组木犀草素+连翘(50mg+15g)木犀草素+连翘(50mg+30g)木犀草素+连翘(50mg+60g) | -5010505050 | 3.232±0.4331.587±0.321**1.311±0.217**0.975±0183**#0.754±0.136**#0.582±0091**# | 7.21±1.324.23±0.95**3.79±0.75**2.13±0.61**#1.69±0.47**#1.14±0.37**# |
批次 | 连翘苷含量(%) | 得率(%) |
123 | 15.1114.8714.54 | 0.870.960.98 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005101042233A CN1947747B (zh) | 2005-10-10 | 2005-10-10 | 由木犀草素和连翘制成的药物组合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005101042233A CN1947747B (zh) | 2005-10-10 | 2005-10-10 | 由木犀草素和连翘制成的药物组合物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1947747A true CN1947747A (zh) | 2007-04-18 |
CN1947747B CN1947747B (zh) | 2012-02-29 |
Family
ID=38017435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005101042233A Expired - Fee Related CN1947747B (zh) | 2005-10-10 | 2005-10-10 | 由木犀草素和连翘制成的药物组合物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1947747B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101099769B (zh) * | 2007-06-25 | 2010-05-19 | 武汉大学 | 连翘在制备抗肿瘤化疗增敏减毒药物中的应用 |
CN102406652A (zh) * | 2011-11-18 | 2012-04-11 | 新乡医学院 | 连翘苷在制备抗慢性粒细胞白血病的药物中的应用 |
CN106063792A (zh) * | 2015-04-23 | 2016-11-02 | 富力 | 连翘苷、连翘苷衍生物、连翘苷/连翘脂素组合物在制备缓解或治疗疼痛的药物的应用 |
CN106692127A (zh) * | 2016-12-12 | 2017-05-24 | 东莞广州中医药大学中医药数理工程研究院 | 木犀草素在制备防治登革热病毒感染的药物中的应用 |
CN106905339A (zh) * | 2017-03-09 | 2017-06-30 | 鲁南制药集团股份有限公司 | 一种从连翘叶中提纯连翘苷元的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1259931C (zh) * | 2003-04-17 | 2006-06-21 | 勾大卉 | 一种连翘油软胶囊 |
CN1493571A (zh) * | 2003-08-25 | 2004-05-05 | 杭州福斯特化学品有限公司 | 木犀草素金属盐及其制备方法和用途 |
-
2005
- 2005-10-10 CN CN2005101042233A patent/CN1947747B/zh not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101099769B (zh) * | 2007-06-25 | 2010-05-19 | 武汉大学 | 连翘在制备抗肿瘤化疗增敏减毒药物中的应用 |
CN102406652A (zh) * | 2011-11-18 | 2012-04-11 | 新乡医学院 | 连翘苷在制备抗慢性粒细胞白血病的药物中的应用 |
CN102406652B (zh) * | 2011-11-18 | 2012-12-05 | 新乡医学院 | 连翘苷在制备抗慢性粒细胞白血病的药物中的应用 |
CN106063792A (zh) * | 2015-04-23 | 2016-11-02 | 富力 | 连翘苷、连翘苷衍生物、连翘苷/连翘脂素组合物在制备缓解或治疗疼痛的药物的应用 |
CN106692127A (zh) * | 2016-12-12 | 2017-05-24 | 东莞广州中医药大学中医药数理工程研究院 | 木犀草素在制备防治登革热病毒感染的药物中的应用 |
CN106692127B (zh) * | 2016-12-12 | 2021-01-15 | 东莞广州中医药大学中医药数理工程研究院 | 木犀草素在制备防治登革热病毒感染的药物中的应用 |
CN106905339A (zh) * | 2017-03-09 | 2017-06-30 | 鲁南制药集团股份有限公司 | 一种从连翘叶中提纯连翘苷元的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1947747B (zh) | 2012-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1954840A (zh) | 一种由绞股蓝、西洋参和黄芪制成的药物组合物 | |
CN1899333A (zh) | 一种柴胡提取物、其制备方法及其应用 | |
CN1748765A (zh) | 一种具有通便排毒、减肥降脂功能的组合物及制备方法 | |
CN1686352A (zh) | 一种治疗高脂血症的药物及其生产方法 | |
CN1245198C (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN1947747A (zh) | 由木犀草素和连翘制成的药物组合物及其制备方法和用途 | |
CN101062084A (zh) | 一种抗肝炎的药物组合物 | |
CN1927312A (zh) | 一种含有葡萄提取物的药物组合物及其制备方法、用途 | |
CN1923241A (zh) | 包括淫羊藿提取物、钩藤提取物、天麻素的药物组合物及其制备方法和应用 | |
CN100341492C (zh) | 一种参芪降糖软胶囊及其制备检测方法 | |
CN1954849A (zh) | 一种白花蛇舌草、人参和黄芪配伍的抗肿瘤的药物组合物 | |
CN101053566A (zh) | 乙酰半胱氨酸或其盐和抗感染药物的组合物 | |
CN1931233A (zh) | 一种用于治疗心脑血管疾病的丹参和淫羊藿的药用组合物 | |
CN1947749A (zh) | 一种由头花蓼和茯苓制成的药物组合物 | |
CN1939417A (zh) | 北豆根与金果榄或其提取物的药物组合物 | |
CN1954870A (zh) | 一种由肿节风和白花蛇舌草制成的药物组合物 | |
CN1947765A (zh) | 由板蓝根和射干制成的药物组合物及其制备方法和用途 | |
CN101028336A (zh) | 一种头花蓼和独一味的药物组合物 | |
CN1954838A (zh) | 一种抗肿瘤的药物组合物 | |
CN1579455A (zh) | 一种治疗大肠湿热证的中药组合物及其制备方法 | |
CN1931216A (zh) | 一种由红花与红景天制成的药物组合物 | |
CN1517326A (zh) | 栀子环烯醚萜总提物及其制备方法和用途 | |
CN1939412A (zh) | 一种由北豆根与新鱼腥草素钠制成的药物组合物 | |
CN1579485A (zh) | 治疗肠功能紊乱的中药组合物及其制备方法 | |
CN1947742A (zh) | 柴胡和黄芩苷的药物组合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: XUAN ZHU SHANDONG MEDICINE TECHNOLOGY CO. Free format text: FORMER OWNER: HUANG ZHENHUA Effective date: 20080530 |
|
C10 | Entry into substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080530 Address after: Tianchen Avenue Ji'nan High-tech Development Zone in Shandong province No. 2518 post encoding: 250101 Applicant after: Shandong Xuanzhu Medical Technology Co., Ltd. Address before: Post encoding No. 2518 block A, Tianchen Avenue Ji'nan High-tech Development Zone in Shandong Province: 250101 Applicant before: Huang Zhenhua |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAIAN SUSHI TECHNOLOGY TRANSFORMATION CENTER CO., Free format text: FORMER OWNER: SHANDONG XUANZHU MEDICAL TECHNOLOGY CO., LTD. Effective date: 20131008 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 JINAN, SHANDONG PROVINCE TO: 226601 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131008 Address after: 226601 No. 8 Yingbin Road, software park, Haian County, Jiangsu Province Patentee after: Haian Su Fu Technology Transfer Center Co., Ltd. Address before: Tianchen Avenue in Ji'nan high tech Development Zone of Shandong province 250101 City No. 2518 Patentee before: Shandong Xuanzhu Medical Technology Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120229 Termination date: 20171010 |
|
CF01 | Termination of patent right due to non-payment of annual fee |